Structure Therapeutics (GPCR) Competitors $26.53 -0.47 (-1.74%) As of 12:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GPCR vs. AXSM, NUVL, VRNA, GRFS, KRYS, ADMA, CYTK, ELAN, PCVX, and RYTMShould you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include Axsome Therapeutics (AXSM), Nuvalent (NUVL), Verona Pharma (VRNA), Grifols (GRFS), Krystal Biotech (KRYS), ADMA Biologics (ADMA), Cytokinetics (CYTK), Elanco Animal Health (ELAN), Vaxcyte (PCVX), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. Structure Therapeutics vs. Axsome Therapeutics Nuvalent Verona Pharma Grifols Krystal Biotech ADMA Biologics Cytokinetics Elanco Animal Health Vaxcyte Rhythm Pharmaceuticals Structure Therapeutics (NASDAQ:GPCR) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation. Does the media favor GPCR or AXSM? In the previous week, Axsome Therapeutics had 5 more articles in the media than Structure Therapeutics. MarketBeat recorded 15 mentions for Axsome Therapeutics and 10 mentions for Structure Therapeutics. Axsome Therapeutics' average media sentiment score of 1.20 beat Structure Therapeutics' score of 0.96 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, GPCR or AXSM? Structure Therapeutics has a beta of -1.35, suggesting that its stock price is 235% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Is GPCR or AXSM more profitable? Structure Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -74.47%. Structure Therapeutics' return on equity of -16.37% beat Axsome Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Structure TherapeuticsN/A -16.37% -15.68% Axsome Therapeutics -74.47%-223.51%-39.88% Do analysts recommend GPCR or AXSM? Structure Therapeutics presently has a consensus target price of $81.29, suggesting a potential upside of 206.39%. Axsome Therapeutics has a consensus target price of $169.87, suggesting a potential upside of 52.69%. Given Structure Therapeutics' higher probable upside, analysts plainly believe Structure Therapeutics is more favorable than Axsome Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Axsome Therapeutics 0 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of GPCR or AXSM? 91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 9.4% of Structure Therapeutics shares are owned by company insiders. Comparatively, 22.4% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has better earnings and valuation, GPCR or AXSM? Structure Therapeutics has higher earnings, but lower revenue than Axsome Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStructure TherapeuticsN/AN/A-$89.62M-$0.79-33.58Axsome Therapeutics$385.69M14.07-$287.22M-$5.99-18.57 Does the MarketBeat Community prefer GPCR or AXSM? Axsome Therapeutics received 448 more outperform votes than Structure Therapeutics when rated by MarketBeat users. However, 88.89% of users gave Structure Therapeutics an outperform vote while only 70.59% of users gave Axsome Therapeutics an outperform vote. CompanyUnderperformOutperformStructure TherapeuticsOutperform Votes3288.89% Underperform Votes411.11%Axsome TherapeuticsOutperform Votes48070.59% Underperform Votes20029.41% SummaryStructure Therapeutics and Axsome Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GPCR vs. The Competition Export to ExcelMetricStructure TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.53B$6.72B$5.49B$7.97BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-36.007.3622.6118.58Price / SalesN/A241.71397.51103.15Price / CashN/A65.8538.1834.62Price / Book2.726.486.704.26Net Income-$89.62M$143.43M$3.22B$248.31M7 Day Performance12.18%1.69%1.26%1.34%1 Month Performance68.02%6.58%3.73%3.92%1 Year Performance-32.53%-2.63%15.82%5.33% Structure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GPCRStructure Therapeutics2.2116 of 5 stars$26.53-1.7%$81.29+206.4%-31.5%$1.53BN/A-36.00136Upcoming EarningsNews CoverageAXSMAxsome Therapeutics4.8364 of 5 stars$103.00-1.4%$169.80+64.9%+52.2%$5.02B$385.69M-17.20380Upcoming EarningsAnalyst ForecastShort Interest ↓Positive NewsNUVLNuvalent1.8879 of 5 stars$69.95-2.4%$115.50+65.1%+11.4%$5.01BN/A-20.1640Upcoming EarningsPositive NewsVRNAVerona Pharma2.9022 of 5 stars$60.07+2.0%$75.43+25.6%+366.5%$4.85B$42.28M-31.2930Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsGRFSGrifols3.8957 of 5 stars$7.01-1.0%N/A+8.1%$4.82B$7.21B5.9926,300KRYSKrystal Biotech4.9058 of 5 stars$161.91-4.0%$220.00+35.9%+10.9%$4.68B$290.52M54.15210Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsADMAADMA Biologics1.4704 of 5 stars$19.64-7.8%$22.50+14.6%+265.0%$4.64B$426.45M70.14530Upcoming EarningsNews CoveragePositive NewsCYTKCytokinetics4.1729 of 5 stars$37.93-3.9%$81.63+115.2%-30.1%$4.52B$18.47M-7.05250Upcoming EarningsInsider TradeELANElanco Animal Health3.9447 of 5 stars$8.48+0.5%$14.67+73.0%-28.0%$4.21B$4.44B21.209,800Upcoming EarningsShort Interest ↑PCVXVaxcyte3.0336 of 5 stars$30.39-0.8%$136.50+349.2%-40.8%$3.91BN/A-6.61160Upcoming EarningsPositive NewsRYTMRhythm Pharmaceuticals3.7061 of 5 stars$60.48-2.0%$74.92+23.9%+64.0%$3.82B$130.13M-13.97140Upcoming EarningsPositive News Related Companies and Tools Related Companies Axsome Therapeutics Alternatives Nuvalent Alternatives Verona Pharma Alternatives Grifols Alternatives Krystal Biotech Alternatives ADMA Biologics Alternatives Cytokinetics Alternatives Elanco Animal Health Alternatives Vaxcyte Alternatives Rhythm Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GPCR) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GPCR Stock Free GPCR Stock Alerts